PCa Commentary | Volume 126 – September 2018
PCa Commentary | Volume 126 – September 2018 Posted by Edward Weber | September 2018 ...
Read More
United States
Long-Term Outcomes of Permanent Brachytherapy
Richard G. Stock, MD, compares long-term overall survival and morbidity outcomes of brachytherapy alone versus a brachytherapy/ external beam combination in intermediate and high risk prostate cancer. He also discusses factors that could affect those outcomes, such as the patient’s intermediate-risk features, duration of androgen deprivation therapy (ADT), and technique of seed implantation.
Read More
How Does Radiobiology Guide Dose, Fraction, and Source Selection?
Seth Blacksburg, MD, MBA, argues that intensity-modulated radiation therapy (IMRT), brachytherapy, hypofractionation, and stereotactic body radiotherapy (SBRT) all have similar efficacy and safety for treating low and intermediate risk prostate cancer. However, patient and physician factors impact which modality will result in optimal outcomes in individual cases.
Read More
Neuroendocrine Tumors | Not so Rare?
Josh Mailman, MBA, the president of NorCal CarciNET, discusses the management of neuroendocrine tumors (NETs) through a patient’s perspective. He reports on overall patients’ attitudes toward Gallium Ga 68-DOTATATE imaging and the newly-approved Lutetium Lu 177 Dotatate therapy, as well as advocacy in the NETs patient community.
Read More
Peptide Receptor Radionuclide Therapy for NETS
Erik S. Mittra, MD, PhD, explains the literature and rationale behind peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs), including reviewing the NETTER-1 trial that led to its approval. He then discusses the practical aspects and clinical practice of PRRT, how to integrate it in a hospital setting, and future directions for this therapy.
Read More